| Home > Publications Database > Seeding variability of different alpha synuclein strains in synucleinopathies. |
| Journal Article | DZNE-2020-06990 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2019
Wiley-Blackwell
Hoboken, NJ
This record in other databases:
Please use a persistent id in citations: doi:10.1002/ana.25446
Abstract: Currently, the exact reasons why different α-synucleinopathies exhibit variable pathologies and phenotypes are still unknown. A potential explanation may be the existence of distinctive α-synuclein conformers or strains. Here, we intend to analyze the seeding activity of dementia with Lewy bodies (DLB) and Parkinson's disease (PD) brain-derived α-synuclein seeds by real-time quaking-induced conversion (RT-QuIC) and to investigate the structure and morphology of the α-synuclein aggregates generated by RT-QuIC.A misfolded α-synuclein-enriched brain fraction from frontal cortex and substantia nigra pars compacta tissue, isolated by several filtration and centrifugation steps, was subjected to α-synuclein/RT-QuIC analysis. Our study included neuropathologically well-characterized cases with DLB, PD, and controls (Ctrl). Biochemical and morphological analyses of RT-QuIC products were conducted by western blot, dot blot analysis, Raman spectroscopy, atomic force microscopy, and transmission electron microscopy.Independently from the brain region, we observed different seeding kinetics of α-synuclein in the RT-QuIC in patients with DLB compared to PD and Ctrl. Biochemical characterization of the RT-QuIC product indicated the generation of a proteinase K-resistant and fibrillary α-synuclein species in DLB-seeded reactions, whereas PD and control seeds failed in the conversion of wild-type α-synuclein substrate.Structural variances of α-synuclein seeding kinetics and products in DLB and PD indicated, for the first time, the existence of different α-synuclein strains in these groups. Therefore, our study contributes to a better understanding of the clinical heterogeneity among α-synucleinopathies, offers an opportunity for a specific diagnosis, and opens new avenues for the future development of strain-specific therapies. Ann Neurol 2019;85:691-703.
Keyword(s): Aged (MeSH) ; Aged, 80 and over (MeSH) ; Brain: metabolism (MeSH) ; Brain: pathology (MeSH) ; Brain Chemistry: physiology (MeSH) ; Female (MeSH) ; Humans (MeSH) ; Male (MeSH) ; Protein Isoforms: analysis (MeSH) ; Protein Isoforms: metabolism (MeSH) ; Spectrum Analysis, Raman: methods (MeSH) ; Synucleinopathies: metabolism (MeSH) ; Synucleinopathies: pathology (MeSH) ; alpha-Synuclein: analysis (MeSH) ; alpha-Synuclein: metabolism (MeSH)
|
The record appears in these collections: |